FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
Estimated average burden											
I	hours per response:	0 5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person SMITH IAN F					VE	VERTEX PHARMACEUTICALS INC / MA [VRTX]											ck all applicable) Director Officer (give title below)		10% Owr		vner
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 11/03/2017											EVP, COO					
				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)											6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	N M	[A	02210												- 1	X		iled by Mor	•	orting Person One Repo	
(City)	(S	tate)	(Zip)																		
		Tab	le I - Noi	n-Deriv	ative	Se	curit	ies Ac	quire	d, D	isp	osed o	of, c	or Ben	eficia	lly C	Owned	Ī			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ır) i	2A. Deemed Execution Date, if any (Month/Day/Year)		Co	Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				4 and Sec Ben Owr		Amount of ecurities eneficially wned Following		n: Direct r Indirect estr. 4)	7. Nature of Indirect Beneficial Ownership	
									Cod	de V		Amount		(A) or (D)	Price		Reported Transact (Instr. 3	tion(s)			(Instr. 4)
Common Stock				11/03	11/03/2017				N	1		2,155	5	A	\$91.0	05	43,	3,043		D	
Common Stock				11/03	3/2017				S(1)		2,155	5	D	\$150		40,888			D	
Common Stock			11/06	11/06/2017				N	1		4,250)	A	\$77.31		45,138			D		
Common Stock			11/06	11/06/2017				S ⁽	1)		4,250)	D	\$150		40,888		D			
Common Stock															5,306			I	401(k)		
		Т	able II -									sed of onverti				y Ov	vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transac Code (II		of Deri Sec Acq (A) Disp of (I	oosed D) tr. 3, 4	Expira	5. Date Exercisal Expiration Date Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		Amount	Der	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	sable		xpiration ate	Title	- 1	Number of Shares						

(2)

(3)

2,155

4,250

Explanation of Responses:

\$91.05

\$77.31

- $1.\ Transaction\ made\ pursuant\ to\ Mr.\ Smith's\ company-approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. The option vests in 16 quarterly installments from 2/2/2016.
- 3. The option vests in 16 quarterly installments from 2/5/2014.

11/03/2017

11/06/2017

Remarks:

Stock Option

Stock Option

Buy)

(Right to Buy)

(Right to

/s/ Omar White, Attorney-in-

2.155

4,250

\$0.00

\$0.00

11/07/2017

19,397

4,250

D

D

Fact

Common

Stock

Common

Stock

02/01/2026

02/04/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

M

M

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.